Menu Search
Equities

Shanghai Haohai Biological Technology Co Ltd

5HB:FRA

Shanghai Haohai Biological Technology Co Ltd

Actions
  • Price (EUR)3.44
  • Today's Change-0.14 / -3.91%
  • Shares traded470.00
  • 1 Year change-1.71%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.

  • Revenue in HKD (TTM)2.93bn
  • Net income in HKD479.85m
  • Incorporated2007
  • Employees2.18k
  • Location
    Shanghai Haohai Biological Technology Co Ltd4F, No 2 Building, Alley 139Anshun Road, Changning DistrictSHANGHAI 200336ChinaCHN
  • Phone+86 2 152293555
  • Fax+86 2 152293558
  • Websitehttps://www.3healthcare.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.